In UK GLP-1 coverage, these words are often treated as if they mean the same thing. They do not. A medicine can be licensed for one use but not another, approved in a different country but not in the UK, technically available only through restricted pathways, or privately prescribed without being routine NHS access.
As of 23 April 2026, “available” is usually the least useful word unless it is tied to a specific route such as licensed in the UK, available on the NHS under criteria, privately prescribable after consultation, or not a legitimate UK route at all.
People often see headlines saying a product is approved, available, or now in the UK without being told whether that means a UK licence, an NHS pathway, a private prescribing route, or a different country’s decision.
This is the cleanest way to read the language used across clinics, news stories, and comparison pages.
| Term | What it usually means | What it does not automatically mean | UK example |
|---|---|---|---|
| Licensed in the UK | The MHRA has authorised the medicine for specific uses. | That every route, brand variation, or indication is licensed too. | Wegovy is licensed for weight loss and management in eligible patients; Ozempic and Rybelsus are licensed for diabetes. |
| Approved in the U.S. | The FDA has approved the medicine for the U.S. market. | That the UK already has the same approval or practical access. | Foundayo/orforglipron FDA approval is important, but it is not yet the same as a UK availability answer. |
| Available on the NHS | Accessible through NHS pathways for people who meet the criteria. | Open access for everyone who asks. | NICE semaglutide guidance keeps Wegovy access within specialist weight management services and for a maximum of two years. |
| Privately available | Can be prescribed privately after proper clinical review. | That it is automatically appropriate, NHS-funded, or free from restrictions. | GLP-1 medicines can be prescribed privately after consultation through legitimate routes. |
| Obtainable online | Could mean anything from a legitimate online pharmacy to an unsafe seller. | That the product is part of legitimate UK medical access. | GOV.UK warns against beauty salons, social media supply, and unregulated sellers. |
Rybelsus is a real UK oral semaglutide medicine, but it is licensed for adults with type 2 diabetes. That is not the same as saying it is a UK weight-loss tablet.
Wegovy is licensed in the UK and can be available on the NHS, but NICE ties that to eligibility rules, specialist services, and a maximum treatment window.
FDA approval matters for the future of oral GLP-1 medicines, but it should still be described as a U.S. development unless and until the UK position changes.
A medicine can exist in the UK and still have a narrow practical route. A medicine can also exist in one brand or route without creating a broad answer for the whole category.
That word still needs unpacking. Does it mean UK licence, private prescribing, NHS eligibility, or simply that someone somewhere is offering something for sale?
That is one of the biggest category mistakes. U.S. and UK regulatory timelines move differently, and the practical UK answer can remain unchanged for some time after a U.S. headline.
GOV.UK explicitly warns against unregulated sellers, beauty salons, and social media supply routes. That is not the same thing as proper clinical availability.
Name the country every time a regulatory change matters.
Name the indication, not just the brand.
If you say “available”, say through which route.
Keep NHS access, private prescribing, and unsafe online supply on different rails.
The point of this page is to stop one loose word from doing four jobs. Each term is tied back to the kind of official source that can actually support it.
| Term | Best evidence source | Bad shortcut to avoid |
|---|---|---|
| Licensed in the UK | UK regulator or UK public guidance. | Do not infer a UK licence from a U.S. approval. |
| Approved in the U.S. | FDA announcement, approvals table or label. | Do not translate it into UK launch, NHS route or private supply. |
| Available to a UK reader | A legal prescribing and supply route plus current UK clinical context. | Do not treat search visibility, adverts or social-media sellers as access. |
Current UK public guidance on GLP-1 medicines, licensed-use distinctions, pregnancy, contraception, side effects and safe supply.
Regulatory product context for oral semaglutide tablets in the European medicines framework.
U.S. approval context for Foundayo (orforglipron), dated 1 April 2026.
UK public-health context for obesity treatment routes and clinical support.